EXCITATORY AMINO ACID BINDING SITES IN THE BASAL GANGLIA OF THE RAT: A QUANTITATIVE AUTORADIOGRAPHIC STUDY

R. L. ALBIN, R. L. MAKOWIEC, Z. R. HOLLINGSWORTH, L. S. DURE IV, J. B. PENNEY and A. B. YOUNG*

Department of Neurology, University of Michigan, Ann Arbor, MI 48109, U.S.A.

Abstract—Quantitative receptor autoradiography was used to determine the distribution of excitatory amino acid binding sites in the basal ganglia of rat brain. α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid, N-methyl-D-aspartate, kainate, quisqualate-sensitive metabotropic and non-N-methyl-D-aspartate, non-kainate, non-quisqualate glutamate binding sites had their highest density in striatum, nucleus accumbens, and olfactory tubercle. Kainate binding was higher in the lateral striatum but there was no medial-lateral striatal gradient for other binding sites. N-Methyl-D-aspartate and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding sites were most dense in the nucleus accumbens and olfactory tubercle. There was no dorsal-ventral gradient within the striatal complex for the other binding sites. Other regions of the basal ganglia had lower densities of ligand binding. To compare binding site density within non-striatal regions, binding for each ligand was normalized to the striatal binding density. When compared to the striatal complex, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid and metabotropic binding sites had higher relative density in the globus pallidus, ventral pallidum, and subthalamic nucleus than other binding sites. Metabotropic binding also had a high relative density in the substantia nigra. Non-N-methyl-D-aspartate, non-kainate, non-quisqualate glutamate binding sites had a high relative density in globus pallidus, ventral pallidum, and substantia nigra. N-Methyl-D-aspartate binding sites had a low relative density in pallidum, subthalamic nucleus, substantia nigra and ventral tegmental area.

Our data indicate heterogeneous distribution of excitatory amino acid binding sites within rat basal ganglia and suggest that the character of excitatory amino acid-mediated neurotransmission within the basal ganglia is also heterogeneous.

The basal ganglia are a group of interconnected subcortical nuclei spanning the telencephalon, diencephalon, and mesencephalon. While the functions of the basal ganglia are incompletely understood, it is known from both human clinical and experimental animal studies that the basal ganglia are involved in the organization of a wide variety of motor and non-motor behaviors. Biochemical, physiological, behavioral, and immunocytochemical data indicate that excitatory amino acids (EAAs) are important neurotransmitters of afferents to basal ganglia nuclei and of some circuits within the basal ganglia (see below). The best studied of these pathways is the corticostriate projection, where biochemical, physiological, immunocytochemical, and [3H]-aspartate retrograde tracing studies have provided strong evidence that the primary neurotransmitter of corticostriate neurons is an EAA. In addition, other striatal afferents, including those from the amygdala, the parafascicular nucleus, and the subthalamic nucleus (STN) may utilize EAAs as a neurotransmitter. Other basal ganglia nuclei appear to receive EAergic inputs. Recent physiological and immunocytochemical studies suggest that the STN, which sends substantial projections to the pallidum and substantia nigra (SN), is excitatory and uses an EAA as its neurotransmitter. Biochemical and tract-tracing studies have suggested that there is an EAergic projection to the SN and ventral tegmental area (VTA) from the frontal cortex. The STN itself appears to receive a large projection from cortex and physiological evidence indicates that this projection is EAergic.

EA receptors have been subdivided into subtypes based on their response to relatively selective agonists. These receptors appear to possess distinctive physiological properties. The kainate receptor, and the quisqualate-sensitive and α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-sensitive receptor mediate conventional fast synaptic neurotransmission by activation of ligand-gated ion channels. The N-methyl-D-aspartate (NMDA) receptor activates a cation channel which is gated by magnesium in a voltage-dependent fashion. NMDA receptors are thought to mediate some forms of...
synaptic plasticity. A quisqualate-sensitive, but AMPA-insensitive EAA receptor coupled to inositol phospholipid metabolism (the metabotropic receptor) has been described recently. The metabotropic receptor presumably produces neuromodulation rather than conventional fast neurotransmission. In addition to these relatively well-characterized receptor subtypes, we have described recently a neuronal \(^{[3H]}\)glutamate binding site of unknown physiological significance and unique pharmacology. This non-NMDA, non-kainate, non-quisqualate (NNKQ) \(^{[3H]}\)glutamate binding site has a unique regional distribution within the CNS and undergoes significant changes in regional distribution during postnatal development. The existence of EAA receptor subtypes with distinctive physiological characteristics suggests that the postsynaptic effects of EAAs at a given synapse or within a given region are likely to be complex and possibly related to the relative density of EAA receptor subtypes. EAA receptor subtype distribution within the basal ganglia may play a major role in determining the character of EAA-mediated neurotransmission within specific basal ganglia nuclei.

Previous autoradiographic studies have identified EAA receptor subtypes within the basal ganglia. No study, however, has systematically analysed the distribution of all EAA receptor subtypes in these nuclei. Recent refinements in autoradiographic assays permit better delineation of EAA binding sites. As a prelude to further studies on EAA function within the basal ganglia we used quantitative receptor autoradiography to determine the distribution of EAA binding sites within the basal ganglia of the rat.

**EXPERIMENTAL PROCEDURES**

**Materials**

\(^{[3H]}\)Glutamate (specific activity, 46 Ci/mmol) and \(^{[3H]}\)Kainate (specific activity, 4.4 Ci/mmol) were purchased from Amersham Inc. (Arlington Heights, IL). \(^{[3H]}\)AMPA (specific activity, 29 Ci/mmol) was purchased from DuPont/NEN (Boston, MA). Non-radioactive quisqualate, AMPA and NMDA were purchased from Cambridge Research Biochemicals Inc. (Valley Stream, NY). The remaining reagents were purchased from Sigma Chemicals (St Louis, MO) and were of the highest possible purity.

**Tissue preparation**

Fifteen male Sprague-Dawley rats (Harlan Labs, Indianapolis, IN; weight, 175-200 g) were decapitated, their brains rapidly removed and frozen in powdered dry ice. Twenty-micrometer-thick sections were cut on a Lipshaw cryostat. Eight animals were sectioned in the coronal plane at five different rostrocaudal levels. These levels included the caudoputamen-nucleus accumbens-olfactory tubercle (COT), the globus pallidus (GP)-ventral pallidum (VP), the entopeduncular nucleus, the STN, and the SN-VTA. Seven animals were sectioned in a parasagittal plane at two different levels approximately 1.9 and 2.4 mm from the midline. Sections were thaw-mounted onto gelatin-coated slides on a warming plate and stored at -20°C until the time of assay. All assays were run 24-48 h after being killed. Eight animals (four cut in the coronal plane and four cut in the sagittal plane) were used for assay of kainate and NNKQ binding sites. Seven animals (four cut coronally and three parasagittally) were used for assay of AMPA, metabotropic and NMDA binding sites.

**Receptor autoradiography**

Triplicate slides for assay of both total and nonspecific binding of each binding site were obtained at every level of sectioning. Quantitative receptor autoradiography for AMPA and kainate binding sites was performed with \(^{[3H]}\)AMPA and \(^{[3H]}\)kainate, respectively, using conventional autoradiographic techniques (Table I).** NMDA binding sites were assayed with \(^{[3H]}\)glutamate in the pres-
ence of blocking agents (Table 1). Metabotropic binding sites were assayed with [3H]glutamate in the presence of selective blockers according to the method of Cha et al.4 (Table 1) and the NNKQ binding sites were assayed with [3H]AMPA. Metabotropic binding was measured with the addition of 100 μM kainate. For AMPA binding sites, the concentration of [3H]AMPA was 34 nM, and nonspecific binding was measured with the addition of 1 mM glutamate. For NMDA binding sites, the concentration of [3H]glutamate was 60 nM and nonspecific binding was measured with the addition of 1 mM glutamate. Metabotropic binding site density was assayed with 100 nM [3H]glutamate, and nonspecific binding was measured with the addition of 2.5 μM quisqualate. NNKQ binding sites were measured with 30 nM [3H]glutamate diluted with 170 nM non-radioactive glutamate (final specific activity, 6.9 Ci/mmol) in the presence of 1 mM NMDA, 1 mM kainate, and 2.5 μM quisqualate, and nonspecific binding was measured with 1 mM glutamate. For AMPA, kainate, and NMDA binding, nonspecific binding represented less than 10% of total binding. Nonspecific binding was approximately 25% of total NNKQ binding and approximately 50% of total metabotropic binding.

All assays were performed in an identical manner. Slides were warmed to room temperature, immersed in incubation buffer at 4°C for 30 min and dried under a stream of cool air. Sections were then placed in incubation buffer at 4°C containing a single concentration of radioactive ligand (Table 1) and appropriate blocking agents (Table 1) for 45 min. Incubation was terminated by removal of slides from the ligand solution and rapid rinsing with four 4-ml squirts of 4°C buffer followed by two 3-ml squirts of 2.5% glutaraldehyde in acetone. Slides were then dried under a stream of hot air and apposed to tritium-sensitive film (Hyperfilm, Amersham) in light-tight cassettes along with standards containing known amounts of radioactivity. After two to six weeks, films were developed in Kodak D-19.

Data analysis

Ligand binding was quantitated with computer-assisted densitometry using the MCID system (Imaging Research Inc., St Catharines, Ontario). To quantify ligand binding density, the optical density of co-exposed standards was determined and a standard curve generated by fitting standard values with a fourth-degree polynomial regression equation.6 Standards were either specially made 14C plastic standards67 or commercial 14C plastic standards (ARC Inc., St Louis, MO), both calibrated against previously described 3H-brain paste standards.68 The 3H-brain paste standards are constructed to give a known amount of radioactivity per picomole of protein.67 Use of the standards and derived standard curve allows conversion of areal optical density to pmol/mg protein values.69 This technique does assume, however, that protein concentration is reasonably uniform across brain regions. Areas read included the medial striatum, lateral striatum, nucleus accumbens, OT, GP, ventral pallidum (VP), entopeduncular nucleus (EP), STN, and VTA. Medial striatum and lateral striatum were read separately because hodological and behavioral studies indicate that these areas have different functional features.50,51 The striatum viewed in the coronal plane was bisected to distinguish lateral striatum from medial striatum. When comparing data from lateral striatum and medial striatum, only readings from coronally sectioned animals were used. It was impossible to reliably differentiate substantia nigra pars compacta from substantia nigra pars reticulata and SN readings are an aggregate of the two regions weighted towards the pars reticulata because of its greater extent. All regions were read with a variable size cursor to allow sampling of the entire area of the structure(s) of interest present on each film. Assay of receptors with a single concentration of ligand does not allow strict comparison of receptor subtype density. Performance of saturation or displacement curves for small structures such as the STN, EP, and VTA is quite difficult. To assess the relative density of receptor subtypes within non-striatal basal ganglia nuclei, we normalized the density of binding sites within non-striatal nuclei by calculating the percentage of striatum–nucleus accumbens–OT complex binding site density for binding sites within non-striatal nuclei (Table 2). Since receptor density for all ligands (see below) was quite high in the striatal complex, the percentage of striatal binding serves as a basis for a comparative index of absolute receptor density.

Differences between the amount of given ligand bound within different areas of the same region were assessed with a paired t-test. Areas compared with the t-test included the lateral striatum and medial striatum, dorsal striatum (mean of lateral striatum and dorsal striatum from the coronally sectioned animals averaged with dorsal striatum from parasagitally sectioned animals) and ventral striatum (mean of nucleus accumbens and OT), and the GP and VP. To compare statistically the density of different binding sites within non-striatal regions, the percentages of striatal complex binding for each binding site in each non-striatal region were compared with each other using one-way analysis of variance followed by post hoc Newman–Keuls testing for individual comparisons.

RESULTS

Striatum nucleus accumbens olfactory tubercle

Among basal ganglia nuclei, these three regions had the highest density of all EAA binding sites (Table 2, Figs 1–4). With the exception of kainate binding, the density of ligand binding was similar between the medial striatum and lateral striatum (Tables 2, 3, Figs 1, 3). Kainate binding sites were slightly but significantly more dense in the lateral striatum (Tables 2, 3, Fig. 3). Kainate, metabotropic, and NNKQ binding sites had similar density in the striatum, nucleus accumbens, and OT (Tables 2, 3, Figs 1, 3, 4). NMDA and AMPA binding sites, however, had a dorsal–ventral density gradient with highest density of binding in the nucleus accumbens and OT (Tables 2, 3, Figs 1, 2).

Globus pallidus–ventral pallidum

In all assays the density of ligand binding was substantially lower in the GP and VP than in the striatum–nucleus accumbens–OT (Table 2, Figs 1–4). VP, however, had a consistently higher density of bound ligand than GP (Tables 2, 3, Figs 1–4). Relative to the striatal regions, there were some differences between receptor subtypes in the GP–VP. GP, NMDA and kainate binding sites had particularly low densities relative to the striatum (Tables 2, 3, Figs 2, 3). AMPA, metabotropic, and NNKQ binding sites had greater relative densities than NMDA or kainate binding sites in the GP (Tables 2, 3) and these differences were statistically significant (Table 3). In the VP, metabotropic, kainate, AMPA, and NNKQ binding had higher relative densities than NMDA binding sites (Tables 2, 3). Analysis of variance indicated that metabotropic, kainate, AMPA, and NNKQ binding sites comprised a single
Table 2. Density of excitatory amino acid binding sites in rat basal ganglia

<table>
<thead>
<tr>
<th>Region</th>
<th>NMDA</th>
<th>AMPA</th>
<th>MET</th>
<th>KA</th>
<th>NNKQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral striatum†</td>
<td>0.673</td>
<td>2.417</td>
<td>0.694</td>
<td>1.044</td>
<td>1.513</td>
</tr>
<tr>
<td>(0.016)</td>
<td>(0.031)</td>
<td>(0.052)</td>
<td>(0.172)</td>
<td>(0.193)</td>
<td></td>
</tr>
<tr>
<td>Medial striatum†</td>
<td>0.676</td>
<td>2.559</td>
<td>0.738</td>
<td>0.958</td>
<td>1.493</td>
</tr>
<tr>
<td>(0.06)</td>
<td>(0.082)</td>
<td>(0.076)</td>
<td>(0.179)</td>
<td>(0.140)</td>
<td></td>
</tr>
<tr>
<td>Dorsal striatum‡</td>
<td>0.68</td>
<td>2.787</td>
<td>0.734</td>
<td>0.894</td>
<td>1.500</td>
</tr>
<tr>
<td>(0.016)</td>
<td>(0.105)</td>
<td>(0.035)</td>
<td>(0.091)</td>
<td>(0.167)</td>
<td></td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>1.002</td>
<td>2.712</td>
<td>0.767</td>
<td>0.9843</td>
<td>1.527</td>
</tr>
<tr>
<td>(0.039)</td>
<td>(0.286)</td>
<td>(0.084)</td>
<td>(0.091)</td>
<td>(0.133)</td>
<td></td>
</tr>
<tr>
<td>OT</td>
<td>1.25</td>
<td>2.585</td>
<td>0.834</td>
<td>1.015</td>
<td>1.373</td>
</tr>
<tr>
<td>(0.063)</td>
<td>(0.322)</td>
<td>(0.093)</td>
<td>(0.093)</td>
<td>(0.140)</td>
<td></td>
</tr>
<tr>
<td>Ventral striatum§</td>
<td>1.127</td>
<td>2.666</td>
<td>0.818</td>
<td>0.997</td>
<td>1.427</td>
</tr>
<tr>
<td>(0.031)</td>
<td>(0.309)</td>
<td>(0.086)</td>
<td>(0.086)</td>
<td>(0.133)</td>
<td></td>
</tr>
<tr>
<td>Striatal complex*</td>
<td>0.903</td>
<td>2.467</td>
<td>0.772</td>
<td>0.975</td>
<td>1.500</td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>0.081</td>
<td>0.626</td>
<td>0.181</td>
<td>0.138</td>
<td>0.533</td>
</tr>
<tr>
<td>(0.012)</td>
<td>(0.054)</td>
<td>(0.03)</td>
<td>(0.01)</td>
<td>(0.060)</td>
<td></td>
</tr>
<tr>
<td>VP</td>
<td>0.173</td>
<td>0.864</td>
<td>0.363</td>
<td>0.443</td>
<td>0.740</td>
</tr>
<tr>
<td>(0.033)</td>
<td>(0.036)</td>
<td>(0.045)</td>
<td>(0.030)</td>
<td>(0.087)</td>
<td></td>
</tr>
<tr>
<td>EP</td>
<td>0.064</td>
<td>0.41</td>
<td>0.159</td>
<td>0.233</td>
<td>0.280</td>
</tr>
<tr>
<td>(0.006)</td>
<td>(0.010)</td>
<td>(0.030)</td>
<td>(0.037)</td>
<td>(0.027)</td>
<td></td>
</tr>
<tr>
<td>STN</td>
<td>0.161</td>
<td>0.778</td>
<td>0.377</td>
<td>0.285</td>
<td>0.223</td>
</tr>
<tr>
<td>(0.015)</td>
<td>(0.051)</td>
<td>(0.059)</td>
<td>(0.042)</td>
<td>(0.053)</td>
<td></td>
</tr>
<tr>
<td>SN</td>
<td>0.112</td>
<td>0.578</td>
<td>0.259</td>
<td>0.193</td>
<td>0.613</td>
</tr>
<tr>
<td>(0.014)</td>
<td>(0.025)</td>
<td>(0.038)</td>
<td>(0.042)</td>
<td>(0.040)</td>
<td></td>
</tr>
<tr>
<td>VTA</td>
<td>0.188</td>
<td>0.450</td>
<td>0.11</td>
<td>0.148</td>
<td>0.360</td>
</tr>
<tr>
<td>(0.031)</td>
<td>(0.030)</td>
<td>(0.051)</td>
<td>(0.047)</td>
<td>(0.053)</td>
<td></td>
</tr>
</tbody>
</table>

Units are pmol/mg protein (S.E.M.). Percentages are percentage of binding in region as percentage of binding in the striatal complex.*

*To correct for the greater extent of the dorsal striatum, the striatal complex mean was calculated by adding mean of dorsal striatum twice to means of nucleus accumbens and OT and dividing by four.

†Medial and lateral striatum measurements from animals sectioned in coronal plane.

‡Mean of lateral and medial striatum in coronal sections averaged with striatum from parasagittal sections.

§Mean of nucleus accumbens and OT.

KA, kainate; MET, metabotropic.

Table 3. Results of statistical analysis

<table>
<thead>
<tr>
<th>Regions compared</th>
<th>NMDA</th>
<th>AMPA</th>
<th>MET</th>
<th>KA</th>
<th>NNKQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral striatum vs medial striatum</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>P &lt; 0.025</td>
<td>NS</td>
</tr>
<tr>
<td>Dorsal striatum vs ventral striatum</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.002</td>
</tr>
<tr>
<td>GP vs VP</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>P &lt; 0.001</td>
<td>NS</td>
</tr>
</tbody>
</table>

ANOVA results†

GP
- P < 0.0001; NNKQ > MET (P < 0.05), KA (P < 0.01), NMDA (P < 0.01), AMPA > KA (P < 0.05), NMDA (P < 0.01), MET > NMDA (P < 0.05)

VP
- P < 0.002; NNKQ, KA, MET, AMPA > NMDA (P < 0.05)

EP
- P < 0.0001; NNKQ, KA, MET > NMDA (P < 0.05)

STN
- P < 0.006; MET > NNKQ (P < 0.01), KA (P < 0.01), AMPA (P < 0.05), NMDA (P < 0.01)

SN
- P < 0.0001; NNKQ > NMDA (P < 0.01), AMPA (P < 0.01), MET (P < 0.05), KA (P < 0.01), MET > NMDA (P < 0.01)

VTA
- NS

*Results of paired t-test.

†Results of analysis of variance with significance of one-way ANOVA followed by results of significant post hoc Newman–Keuls individual comparisons. Individual Newman–Keuls comparisons that are not significant are not shown.

KA, kainate; MET, metabotropic; NS, not significant.
Fig. 1. A, B (caption overleaf).
Basal ganglia glutamate receptors

Fig. 2. Histograms of NMDA and AMPA binding site density in the basal ganglia. Error bars are S.E.M. STRL, lateral striatum; STRM, medial striatum; STRD, dorsal striatum; ACC, nucleus accumbens; STRV, ventral striatum.

Entopeduncular nucleus

This region had a low relative density of all binding site subtypes (Table 2, Figs 1–4). As with the VP, the relative density of NMDA binding sites was lower than AMPA, metabotropic, kainate, and NNKQ relative binding site density with the relative densities of the latter four binding sites forming one group (Table 3).

Subthalamic nucleus

The relative density of NMDA and NNKQ binding sites was low (Tables 2, 3, Figs 2, 4). AMPA and kainate binding site densities were almost one-third of striatal complex binding and metabotropic binding site density was almost 50% of striatal complex

Fig. 1. Parasagittal autoradiographs of EAA binding sites in the basal ganglia. (A) NMDA, (B) AMPA, (C) metabotropic, (D) kainate, (E) NNKQ. STR, dorsal striatum; ACC, nucleus accumbens. Metabotropic binding site image prepared by digital subtraction of $[^3H]$glutamate binding under metabotropic binding site conditions (see Table 1 and text) in the presence of 2.5 μM quisqualate from total $[^3H]$glutamate binding under metabotropic binding site conditions. Digital subtraction is done by computationally superimposing images from two closely adjacent sections and computing the difference of superimposed pixels. An image is constructed using the derived values for individual pixels. Digital subtraction is done with images from this assay because of the relatively high nonspecific binding. Magnification = x 10 prior to reduction.
binding (Table 2, Figs 2, 3). Only the relative density of metabotropic binding was statistically distinguishable from the relative density of other binding sites (Table 3).

**Substantia nigra–ventral tegmental area**

The relative density of all binding sites was low in SN and VTA with the exception of metabotropic and NNKQ binding in the SN (Tables 2, 3, Figs 1–4). The latter was approximately 40% of striatal complex binding (Table 2, Fig. 4). The relative densities of metabotropic and NNKQ binding were significantly different from the relative densities of the other binding sites (Table 3). There were no significant differences among relative densities of binding sites in the VTA (Tables 2, 3).

**DISCUSSION**

All nuclei of the basal ganglia possessed EAA binding sites but EAA binding site subtypes were distributed inhomogeneously in rat basal ganglia. Strict comparison of the total density ($B_{\text{max}}$) of binding site subtypes within a given region was not possible using single ligand concentrations. Scatchard analyses, however, were not feasible in several regions due to their small size. Nonetheless, by comparing the amount of bound ligand relative to binding within the striatum–nucleus accumbens–OT complex, a region with a high density of all EAA binding site subtypes, it is possible to approximate the relative density of EAA binding site subtypes within and among basal ganglia nuclei. This type of analysis assumes that...
receptor affinity is reasonably similar in different basal ganglia nuclei. Prior studies of EAA binding sites have found little variation in the affinity of EAA binding sites between regions with the exception of NMDA binding sites which may exist in both agonist-prefering and antagonist-prefering forms in different regions.33,58,59

**Striatal complex**

The binding site density differences between basal ganglia nuclei are most marked by the higher density of all binding sites in the striatum–nucleus accumbens–OT complex than other nuclei of the basal ganglia. Of all basal ganglia nuclei, the striatum–nucleus accumbens–OT complex probably receives the greatest amount of EAAergic innervation. In addition to the massive and well-characterized input from neocortex to the striatum proper,23,24,29,30,40,48,54,75,80,94 the striatum nucleus accumbens–OT complex also receives probable EAAergic input from the hippocampal complex,24 amygdala,26,93 and primary olfactory cortex.26 The striatum–nucleus accumbens–OT complex may also receive EAAergic afferents from the intralaminar nuclei of the thalamus. Retrograde [H]aspartate transport studies indicate that these nuclei may be EAAergic.26 Studies of striatal EAA uptake after parafascicular nucleus lesions, however, do not support this notion.65 The striatal complex also receives a potentially EAAergic input from the STN. While the STN–striatal projection is relatively modest in rat,36,48 in primates and cat it appears to be a more substantial striatal afferent.14,58 The relatively high density of all EAA binding sites within all components of the striatum–nucleus accumbens–OT complex emphasizes the similarity of dorsal striatum, nucleus accumbens, and OT.3

Our NMDA, AMPA, and kainate data are consistent with previous studies of striatal EAA binding sites in rat brain.32,37,37,64,66,70 Our results correlate with studies showing that intrastriatal infusion of agents active at either NMDA, AMPA, or kainate receptors produce prominent behavioral effects.22,41,45,85 Our metabotropic binding data are also compatible with evidence that glutamate and quisqualate agonists are potent stimulators of inositol phospholipid turnover in striatal slices and striatal neurons in primary culture.64,81,96 Autoradiographic investigations of inositol triphosphate receptors have shown a high density in the striatum.97 Available data suggest that EAA binding sites are predominantly located on striatal neurons though some data suggests the presence of presynaptic EAA receptors on corticostriate and nigrostriatal dopaminergic terminals.15,23,33

Within the striatum–nucleus accumbens–OT complex, our results suggest differences in EAA binding site distribution. Kainate binding was significantly higher in the lateral striatum than the medial striatum, and there is a dorsal–ventral gradient of NMDA and AMPA binding site density with highest density in the ventral striatum and lowest in the dorsal striatum. One possible explanation for this gradient is the greater cellular density of the nucleus accumbens and OT, especially when compared with the dorsal striatum where it is penetrated by myelinated bundles of corticofugal axons. Myelin absorbs tritium emissions, and this “quenching” may cause underestimates of ligand binding.27 Kainate, metabotropic, and NNKQ binding sites, however, have no dorsal–ventral density gradient. The distributions of these binding sites cannot be attributed to neuronal density or white matter gradients and suggest that there is a real dorsal–ventral gradient in NMDA and AMPA binding site density.
Non-striatal nuclei

Another dorsal–ventral gradient exists between the dorsal and ventral pallidum. In this situation, however, all EAA binding site subtypes are more dense in VP than in GP. Due to the fact that the GP is traversed by numerous fibers of passage, neuronal density is higher in VP than GP. Difference in neuronal density is a likely explanation for the higher density of receptors and NNKQ binding in VP than in GP. In addition, many of the fibers passing through the GP are myelinated, and white matter quenching could contribute to the apparently lower density of EAA binding sites in VP. While binding studies with $^{14}$C-labeled ligands would be necessary to systematically evaluate the possible role of quenching, our previous experience with $[^{14}$C]glutamate binding suggests that white matter quenching is not a major determinant of regional differences in binding site density.

Within the GP, AMPA, metabotropic, and NNKQ binding sites had higher relative densities compared to the striatal complex than NMDA or kainate binding sites. GP receives potentially EAergic inputs from the parafascicular nucleus, and a substantial projection from the STN. VP also receives a projection from the STN and Fuller et al. have used [³H]d-aspartate retrograde transport to show a potentially EAergic afferent from the intralaminar thalamic nuclei. AMPA, metabotropic, kainate, and NNKQ binding sites had high relative densities within the VP. Despite the apparently low density of NMDA binding sites, behavioral studies indicate that NMDA receptors may play a significant role in pallidal function. Turski et al. have demonstrated that intra GP infusion of the NMDA antagonist AP7 has significant effects on motor behavior.

The EP has a low density of all EAA binding sites with a particularly low density of NMDA binding sites. As with the GP, the low density of EAA binding sites could be due in part to the low cellular density of the EP and the fact that it is embedded within the fibers of the heavily myelinated internal capsule. Functional EA receptors exist within the EP. Injection of EA antagonists within the EP of primates and rodents has potent effects on motor function. The EP receives a substantial EAergic input from the STN.

The STN itself is known to receive a prominent projection from the neocortex. Extracellular recording studies have established that the cortico-STN projection is responsible for a rapid onset, short duration EAA-mediated excitatory postsynaptic potential in STN neurons, and the pharmacology of this fast excitatory postsynaptic potential is consistent with activation of kainate or AMPA receptors. These physiological results accord well with our binding data demonstrating a relatively high density of AMPA and kainate binding sites within the STN. Metabotropic binding sites are also relatively dense within the STN, suggesting that metabotropic receptors may be an important substrate for plastic changes in STN neuron function induced by cortical activity. While the relative density of NMDA binding sites in STN is low, a recent intracellular recording study indicated that NMDA receptors are involved in the afferent activation of STN neurons.

The STN provides excitatory, EAergic input to the VTA–SN, including both the pars reticulata and pars compacta. The VTA–SN may receive other EAergic inputs. The existence of a corticonigral projection has been controversial, but tract-tracing studies indicate the presence of a frontal corticonigral projection which preferentially terminates on the pars compacta and VTA. Biochemical studies indicate that this projection is EAergic. The SN also receives an excitatory input from the pedunculopontine nucleus (PPN). The PPN–nigral projection has been thought to be cholinergic, however, have shown that SN neuron excitation induced by PPN stimulation is antagonized by EA antagonists and not by the muscarinic anticholinergic scopolamine. The PPN projects also to the GP and EP. Recent studies of PPN connections indicate that non-cholinergic neurons closely adjacent to the cholinergic neurons of the PPN project to the GP, EP, and SN. The PPN is another potential source of EAergic innervation of the basal ganglia.

The SN is distinguished by the presence of a high relative density of metabotropic and NNKQ binding sites. The NNKQ site has also been found to be relatively abundant in human SN. The functional significance of this binding site is presently unknown. Despite their low density, other types of EA receptors may be important in SN–VTA function. Behavioral changes can be induced by intranigral infusion of kainate, NMDA, and AMPA. Electrophysiological studies have demonstrated that nigral and VTA neurons are excited by NMDA and inhibited by NMDA antagonists, and NMDA enhances dopamine release from SN slice preparations. In rat mesencephalic cell cultures, EA-stimulated dopamine release is attenuated by both NMDA and non-NMDA antagonists. Kalivas et al. have suggested that NMDA and kainate receptors are differentially located on different subpopulations of mesencephalic dopaminergic neurons. The preferential localization of NMDA receptors on dopaminergic nigrostriatal neurons is supported by the recent finding that NMDA receptors are preferentially depleted in the SN of Parkinson’s disease victims.

Clinical implications

Our binding studies have potential clinical implications. The presence of EA binding sites within all nuclei of the basal ganglia suggests that EAergic agents could be used therapeutically to modify basal ganglia function. Several groups have suggested that agents interacting with EA receptors might be useful in pharmacotherapy of Parkinson’s disease, and Carlson and Carlson have shown that systemic administration of the non-competi-
tive NMDA antagonist \{(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten 5,10-iminemaleate\} (MK-801) to catecholamine-depleted mice increases motor activity. Injection of competitive or non-competitive NMDA antagonists into the striatum produces an increase in motor activity similar to that seen with dopamine agonists, and infusion of NMDA antagonists into the EP, STN, or SN potentiates the effect of L-DOPA in monoamine-depleted rats. The clinical usefulness of modifying the activity of non-striatal basal ganglia nuclei with systemically administered EAA antagonists may, however, be limited by the relatively low density of EAA binding sites in the GP, VP, EP, SN, VTA, and STN. The high density of EAA binding sites in other forebrain regions suggests that toxic effects might occur before therapeutic benefit is obtained from blockade of EAA receptors in non-striatal basal ganglia nuclei. The striatum–nucleus accumbens–OT complex, with its high density of binding sites, seemingly offers a better target for pharmacological intervention.

CONCLUSION

We have demonstrated the presence of EAA binding sites in all nuclei of the basal ganglia. The distribution of EAA binding sites was heterogeneous both within and between basal ganglia nuclei. While the presence of binding sites in receptor binding assays does not guarantee the presence of neurotransmission mediated by that receptor, our results suggest that EAA-mediated neurotransmission within the basal ganglia has a complex and heterogeneous character.

REFERENCES

19. Collingridge G. L. and Davies J. (1978) An evaluation of \[^{3}H\]alpha-aminoacidopate and \[^{3}H\]alpha-aminoisoburate as selective antagonists of excitatory amino acids in the substantia nigra and mesencephalic reticular formation of the rat. Neuropharmacology 18, 193 199.
gular and efferent projections. Explo Neurol. 105, 36-44.
Neurosci. 13, 325-326.
ami acids from the rat striatum: further evidence for a role of glutamate and aspartate in corticostriatal neurotransmission. J. Neurochem. 47, 98-106.
neostriatum in vivo following stimulation of frontal cortex. Neuroscience 5, 2151-2154.
N-methyl-D-aspartate, quisqualate- and kainate-sensitive glutamate binding sites. J. Pharmaco. exp. Ther. 233, 254-263.
subthalamonomagical pathway in the rat. Brain Res. 151, 235-244.
terminals isolated from basal ganglia and substantia nigra. J. Neurochem. 34, 1130-1139.
concentrations of amino acids, monoamines and acetylcholine and on the ultrastructure in rat striatum. A confirmation 
of glutamate as the specific cortico-striatal transmitter. J. Neurochem. 36, 1087-1098.
42. Herkenham M. (1987) Mismatches between neurotransmitter and receptor localizations in brain: observations and 
mediation by quissuolate or kainate receptors. Neuroscience 14, 417-426.
meditation by quisqualate or kainate receptors. J. comp. Neural. 294, 607-622.
meditation by quisqualate or kainate receptors. J. comp. Neural. 294, 607-622.
study of dopaminergic innervation. Brain Res. 37, 237-246.
48. Klaivas P. W., Duffy P. and Barrow J. (1989) Regulation of the mesocorticolumbic dopamine system by glutamic acid 
52. Klockgether T. and Turski L. (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of 
glutamate content in substantia nigra following corticostriatal ablation in the rat. Brain Res. 322, 124-126.
from the mesopontine tegmentum to the extrapyramidal motor system nuclei. J. comp. Neurol. 275, 469-492.
365-373.
in the rat. Neuroscience 29, 503-517.
58. Monaghan D. T., Bridges R. J. and Colman C. W. (1989) The excitatory amino acid receptors: their classes, 
pharmacology, and distinct properties in the function of the central nervous system. A. Rev. Pharmac. Toxicol. 29, 
365-402.


(Accepted 19 April 1991)